Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion [0.03%]
胶质瘤中DKC1表达上调及其在肿瘤细胞增殖、迁移和侵袭中的意义
Fa-An Miao,Kun Chu,Hai-Rong Chen et al.
Fa-An Miao et al.
The dyskeratosis congenita 1 (DKC1) gene is located on the X chromosome at Xq28. Dyskerin encoded by the DKC1 gene is associated with the formation of certain small RNAs and the telomerase activity. Inherited mutations in DKC1 inactivate th...
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study [0.03%]
低剂量TAS102联合奥沙利铂治疗难治性转移性结直肠癌的Ⅰ期临床研究：LUPIN研究
Mitsukuni Suenaga,Takeru Wakatsuki,Tetsuo Mashima et al.
Mitsukuni Suenaga et al.
Background The effectiveness of reintroducing oxaliplatin for metastatic colorectal cancer (mCRC) refractory to both oxaliplatin and irinotecan was previously reported in a phase II study (RE-OPEN). We conducted a phase I study to determine...
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer [0.03%]
高效药物筛选发现金盐酸能潜在增强小细胞肺癌的顺铂敏感性
Xiaoli Liu,Wei Wang,Yanping Yin et al.
Xiaoli Liu et al.
Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we developed a high-throughput drug screen s...
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors [0.03%]
Pexidartinib（CSF-1R抑制剂）治疗晚期实体瘤的I期临床研究：亚洲患者结果
Jih-Hsiang Lee,Tom Wei-Wu Chen,Chih-Hung Hsu et al.
Jih-Hsiang Lee et al.
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexid...
Clinical Trial
Investigational new drugs. 2020 Feb;38(1):99-110. DOI:10.1007/s10637-019-00745-z 2020
Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors [0.03%]
抗癌药AR-67在实体瘤患者中的群体药代动力学分析
Fei Tang,Eleftheria Tsakalozou,Susanne M Arnold et al.
Fei Tang et al.
Background AR-67 is a novel camptothecin analogue at early stages of drug development. The phase 1 clinical trial in cancer patients with solid tumors was completed and a population pharmacokinetic model (POP PK) was developed to facilitate...
Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma [0.03%]
阿昔替尼药理学治疗药物监测发现即使进行剂量调节，转移性肾细胞癌患者仍存在严重的未充分暴露现象
G Beinse,A Hulin,Benoit Rousseau
G Beinse
Introduction New therapeutic strategies combining axitinib and immune checkpoint blockers are ongoing in metastatic renal cell carcinoma (mRCC). These strategies do not consider the pharmacokinetic variability of axitinib. We aimed to descr...
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage [0.03%]
一种新型DNMT抑制剂通过抑制同源重组损伤提高A549细胞放射敏感性
Hyun-Cheol Kang,Eui Kyu Chie,Hak Jae Kim et al.
Hyun-Cheol Kang et al.
Purpose To elucidate the radiosensitizing effect and underlying mechanism of a new kind of DNA methyltransferase (DNMT) inhibitor with biological availability. Methods A novel non-nucleoside compound, designated as MA-17, was recently deriv...
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations [0.03%]
TAS-121（第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂）治疗携带EGFR突变的非小细胞肺癌患者I期临床研究
Makoto Nishio,Haruyasu Murakami,Yuichiro Ohe et al.
Makoto Nishio et al.
Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients w...
Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer [0.03%]
联合放射治疗通过负载阿糖胞苷的透明质酸水凝胶共轭物瘤内注射在肺癌中发挥协同作用并减少毒性
Juan Tang,Na Wang,JingBo Wu et al.
Juan Tang et al.
The aim of this study was to explore the synergistic anti-tumor effects of cytarabine hyaluronic acid-tyramine (Ara-HA-Tyr) hydrogel conjugates and radiotherapy (RT) in the Lewis lung cancer (LLC) xenograft model, and the mechanisms involve...
Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report [0.03%]
艾乐替尼治疗头颈部新型SQSTM1-ALK融合炎性肌成纤维细胞肿瘤的持久反应：病例报告
Kazunori Honda,Shigenori Kadowaki,Kyoko Kato et al.
Kazunori Honda et al.
An inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm that typically develops in the lungs and seldom in the head and neck region. It is often related to the anaplastic lymphoma kinase (ALK) fusion gene. Crizotinib, a f...